Cryptococcosis

被引:297
作者
Chayakulkeeree, Methee
Perfect, John R.
机构
[1] Duke Univ, Med Ctr, Dept Med, Div Infect Dis & Int Hlth, Durham, NC 27710 USA
[2] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Med,Div Infect Dis & Trop Med, Bangkok 10700, Thailand
[3] Duke Univ, Med Ctr, Dept Microbiol & Mol Genet, Durham, NC 27710 USA
关键词
D O I
10.1016/j.idc.2006.07.001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In the past 2 decades, Cryptococcus has emerged in its clinical significance and as a model yeast for understanding molecular pathogenesis. C neoformans and C gattii are currently considered major primary and secondary pathogens in a wide array of hosts that are known to be immunocompromised or apparently immunocompetent. A recent outbreak of C gattii infections further underscores the clinical importance of the yeast through its epidemiology and pathogenicity features. With an enlarging immunosuppressed population caused by HIV infection, solid organ transplantation, and clinical use of potent immunosuppressives, such as cancer chemotherapy, monoclonal antibodies, and corticosteroids, this fungus has become a well-established infectious complication of modern medicine. This article examines current issues in cryptococcal infections, including new classification, epidemiology, pathogenesis, and specific clinical aspects.
引用
收藏
页码:507 / +
页数:40
相关论文
共 231 条
[31]   COMPLEMENTATION OF A CAPSULE-DEFICIENT MUTATION OF CRYPTOCOCCUS-NEOFORMANS RESTORES ITS VIRULENCE [J].
CHANG, YC ;
KWONCHUNG, KJ .
MOLECULAR AND CELLULAR BIOLOGY, 1994, 14 (07) :4912-4919
[32]   Isolation of the third capsule-associated gene, CAP60, required for virulence in Cryptococcus neoformans [J].
Chang, YC ;
Kwon-Chung, KJ .
INFECTION AND IMMUNITY, 1998, 66 (05) :2230-2236
[33]  
Chang Ying-Shan, 2005, J Chin Med Assoc, V68, P33, DOI 10.1016/S1726-4901(09)70129-7
[34]   CROSS-REACTIVITY BETWEEN STOMATOCOCCUS-MUCILAGINOSUS AND LATEX AGGLUTINATION FOR CRYPTOCOCCAL ANTIGEN [J].
CHANOCK, SJ ;
TOLTZIS, P ;
WILSON, C .
LANCET, 1993, 342 (8879) :1119-1120
[35]   Cryptococcus gattii in AIDS patients, southern California [J].
Chaturvedi, S ;
Dyavaiah, M ;
Larsen, RA ;
Chaturvedi, V .
EMERGING INFECTIOUS DISEASES, 2005, 11 (11) :1686-1692
[36]   Antibody response to Cryptococcus neoformans proteins in rodents and humans [J].
Chen, LC ;
Goldman, DL ;
Doering, TL ;
Pirofski, LA ;
Casadevall, A .
INFECTION AND IMMUNITY, 1999, 67 (05) :2218-2224
[37]   Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand [J].
Chen, S ;
Sorrell, T ;
Nimmo, G ;
Speed, B ;
Currie, B ;
Ellis, D ;
Marriott, D ;
Pfeiffer, T ;
Parr, D ;
Byth, K .
CLINICAL INFECTIOUS DISEASES, 2000, 31 (02) :499-508
[38]   INFECTIONS WITH CRYPTOCOCCUS-NEOFORMANS IN THE ACQUIRED IMMUNODEFICIENCY SYNDROME [J].
CHUCK, SL ;
SANDE, MA .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (12) :794-799
[39]   COMPARISON OF THE SENSITIVITY OF 3 METHODS FOR THE RAPID IDENTIFICATION OF CRYPTOCOCCUS-NEOFORMANS [J].
COHEN, J .
JOURNAL OF CLINICAL PATHOLOGY, 1984, 37 (03) :332-334
[40]   Urease as a virulence factor in experimental cryptococcosis [J].
Cox, GM ;
Mukherjee, J ;
Cole, GT ;
Casadevall, A ;
Perfect, JR .
INFECTION AND IMMUNITY, 2000, 68 (02) :443-448